The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial
Abstract
Background— Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. Methods and Results— This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women ≥18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of ≤35%. The primary outcome was the time to first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke. For the primary composite end point, the hazard ratios were as follows: for warfarin versus aspirin, 0.98 (95% CI, 0.86 to 1.12; P =0.77); for clopidogrel versus aspirin, 1.08 (95% CI, 0.83 to 1.40; P =0.57); and for warfarin versus clopidogrel, 0.89 (95% CI, 0.68 to 1.16; P =0.39). Warfarin was associated with fewer nonfatal strokes than aspirin or clopidogrel. Hospitalization for worsening heart failure occurred in 116 (22.2%), 97 (18.5%), and 89 (16.5%) patients treated with aspirin, clopidogrel, and warfarin, respectively ( P =0.02 for warfarin versus aspirin). Conclusion— The primary outcome measure and the mortality data do not support the primary hypotheses that warfarin is superior to aspirin and that clopidogrel is superior to aspirin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,845
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Garg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Statistical Methods for Survival Data Analysis.
Saggu, P. S., & Lee, E. T. (1994) · The Statistician · doi:10.2307/2348154 · Cited by 628
Dzau, V. J., Packer, M., Lilly, L. S., Swartz, S. L., Hollenberg, N. K., & Williams, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100603 · Cited by 428
van Es, R. F., Jonker, J. J., Verheugt, F. W., Deckers, J. W., & Grobbee, D. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09409-6 · Cited by 423
Cleland, J. G. F., Findlay, I., Jafri, S., Sutton, G., Falk, R., Bulpitt, C., Prentice, C., Ford, I., Trainer, A., & Poole-Wilson, P. A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.010 · Cited by 407
Self-citationβ-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00008 · Cited by 389
Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
Lakatos, E. (1988) · Biometrics · doi:10.2307/2531910 · Cited by 350
Uretsky, B. F., Thygesen, K., Armstrong, P. W., Cleland, J. G., Horowitz, J. D., Massie, B. M., Packer, M., Poole-Wilson, P. A., & Ryden, L. (2000) · Circulation · doi:10.1161/01.cir.102.6.611 · Cited by 334
Self-citationCaptopril-induced Changes in Prostaglandin Production
Swartz, S. L., Williams, G. H., Hollenberg, N. K., Levine, L., Dluhy, R. G., & Moore, T. J. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109788 · Cited by 333
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
(1997) · The Lancet · doi:10.1016/s0140-6736(97)01180-x · Cited by 301
Fat-suppressed breath-hold magnetic resonance coronary angiography.
Manning, W. J., Li, W., Boyle, N. G., & Edelman, R. R. (1993) · Circulation · doi:10.1161/01.cir.87.1.94 · Cited by 282
Al-Khadra, A. S., Salem, D. N., Rand, W. M., Udelson, J. E., Smith, J. J., & Konstam, M. A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00502-0 · Cited by 270
Tea, K. K., Yusuf, S., Pfeffer, M., Kober, L., Hall, A., Pogue, J., Latini, R., & Collins, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11138-x · Cited by 238
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
Hall, D., Zeitler, H., & Rudolph, W. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90449-w · Cited by 237
Al-Khadra, A. S., Salem, D. N., Rand, W. M., Udelson, J. E., Smith, J. J., & Konstam, M. A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00006-0 · Cited by 227
Fiore, L. D., Ezekowitz, M. D., Brophy, M. T., Lu, D., Sacco, J., & Peduzzi, P. (2002) · Circulation · doi:10.1161/hc0502.103329 · Cited by 224
Self-citationAntithrombotic Therapy for Coronary Artery Disease
Harrington, R. A., Becker, R. C., Ezekowitz, M., Meade, T. W., O'Connor, C. M., Vorchheimer, D. A., & Guyatt, G. H. (2004) · Chest · doi:10.1378/chest.126.3_suppl.513s · Cited by 205
Self-citationIncidence of thromboembolic events in congestive heart failure
Dunkman, W. B., Johnson, G. R., Carson, P. E., Bhat, G., Farrell, L., & Cohn, J. N. (1993) · Circulation · Cited by 197
Dunkman, W. B., Johnson, G. R., Carson, P. E., Bhat, G., Farrell, L., & Jn, C. (1993) · PubMed · Cited by 185
Lenarda, A. D. (2000) · PubMed · Cited by 136
Characteristics of Anticoagulant Therapy and Comorbidity Related to Overanticoagulation
Beest, F. P.-V., van Meegen, E., Rosendaal, F. R., & Stricker, B. H. C. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616088 · Cited by 127
Spaulding, C. M., Charbonnier, B., Solal, A. C., Juillière, Y., Kromer, E. P., Ben-Hamda, K., Cador, R., & Weber, S. (1998) · Circulation · doi:10.1161/01.cir.98.8.757 · Cited by 113
Dicumarol Prophylaxis of Thromboembolic Disease in Congestive Heart Failure
Harvey, W. P., & Finch, C. A. (1950) · New England Journal of Medicine · doi:10.1056/nejm195002092420603 · Cited by 106
Massie, B. M., Krol, W. F., Ammon, S. E., Armstrong, P. W., Cleland, J. G. F., Collins, J. F., Ezekowitz, M. D., Jafri, S. M., O’Connor, C. M., Packer, M., et al. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.02.006 · Cited by 101
Self-citationA STUDY OF THE BENEFICIAL EFFECTS OF ANTICOAGULANT THERAPY IN CONGESTIVE HEART FAILURE
GRIFFITH, G. C., Stragnell, R., Levinson, D. C., Moore, F. J., & Ware, A. G. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-5-867 · Cited by 96
The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants
Visser, L. E., Bleumink, G. S., Trienekens, P. H., Vulto, A. G., Albert Hofman, D., & Stricker, B. H. C. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05162.x · Cited by 71
Hall, D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00637-9 · Cited by 34
Interaction between Aspirin and ACE Inhibitors in Patients with Heart Failure
Mah, I., Meune, C., Diemer, M., Caulin, C., & Bergmann, J. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00002 · Cited by 19
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Metadata
- Authors
- Massie, B. M., Collins, J. F., Ammon, S. E., Armstrong, P. W., Cleland, J. G. F., Ezekowitz, M., Jafri, S. M., Krol, W. F., O'Connor, C. M., Schulman, K. A., Teo, K., & Warren, S. R.
- Venue
- Circulation
- Published
- 2009-03-31
- Volume
- 119
- Issue
- 12
- Pages
- 1616-1624
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2163000581
- Cited by
- 408
- References
- 34
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.